|Articles|September 21, 2015
HHS to Fund Regeneron's Efforts for Antibody Against Ebola
Author(s)AJMC Staff
The collaboration will make available 3 fully-humanized monoclonal antibodies to fight the devastating virus.
Advertisement
The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has entered into an agreement with Tarrytown-based Regeneron Pharmaceuticals, Inc to develop a treatment regimen that includes 3 monoclonal antibodies against the Ebola virus.
The company has developed the 3 fully-humanized monclonal antibodies using their propreitory VelociGene and VelocImmune technologies, and will receive $38 million over a 2-year period for further development and manufacturing of the monoclonal antibodies.
Read the associated press release by HHS
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
2
Bringing CAR T-Cell Therapy Into Community Cancer Centers
3
The True Cost of Running a Community CAR T-Cell Program
4
Higher Weight-Adjusted Waist Index Tied to CKD Mortality, Study Finds
5